Pricing Log in Create free account

Gyre Therapeutics, Inc. (GYRE) vs Neurogene Inc. (NGNE)

Gyre Therapeutics, Inc. and Neurogene Inc. are both Biotechnology companies. Gyre Therapeutics, Inc. and Neurogene Inc. are of similar size ($520.3M and $493.1M). Neurogene Inc. has the higher net margin (0.00% vs −21.5%) and the higher return on invested capital (0.00% vs −8.51%). Across the 12 metrics below, Gyre Therapeutics, Inc. leads on 6 and Neurogene Inc. on 6.

Valuation

Metric GYRE NGNE Biotechnology median
P/E n/m n/m 10.85
P/S 4.05 n/m 9.49
P/B 3.41 2.69 2.18
Price to free cash flow n/m n/m 25.85
EV/EBITDA n/m n/m 0.70
EV/Sales 3.48 n/m 8.99
Earnings yield (6.03%) (19.40%) (31.76%)
Free cash flow yield (5.15%) (15.00%) (21.84%)

Profitability

Metric GYRE NGNE Biotechnology median
Gross margin 91.71% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin (21.46%) 0.00% 0.00%
Free cash flow margin (19.94%) 0.00% 0.00%
Return on equity (18.54%) (45.32%) (50.82%)
Return on assets (14.49%) (41.02%) (46.04%)
Return on invested capital (8.51%) 0.00% 0.00%

Growth

Metric GYRE NGNE Biotechnology median
Revenue growth (TTM) 13.51% — 6.96%
EPS growth (last fiscal year) (60.00%) 0.93% 29.88%
Revenue growth, 5-year CAGR 40.96% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GYRE NGNE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.32 10.64 4.84
Net debt to EBITDA (3.74) 2.57 1.01

Dividend

Metric GYRE NGNE Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric GYRE NGNE Biotechnology median
Market cap 493.06m 520.30m 163.56m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack